Oncology Pharmacotherapy and Applications of Biosimilars (OPAB) Program

Registration is complimentary for ISOPP members. Join here now for no-fee: https://www.isopp.org/member-benefits

How to acess: Once logged on as member, click on e-learning in the top purple banner to access the ISOPP e-learning platform and this course. 

Recognizing that there is a rapid expansion of Biosimilars usage in clinical practice, and that the role of an oncology pharmacist is evolving and further integrating as a key member of a multidisciplinary healthcare team, ISOPP developed the Oncology Pharmacotherapy and Applications of Biosimilars (OPAB) online education program that supports oncology pharmacists to safely and confidently introduce Biosimilars into their clinical practice and multidisciplinary healthcare team.

ISOPP presents this education program in a novel way by giving both fundamentals and advanced aspects of 1) pharmacotherapy of various cancers, 2) implementation of biosimilars in oncology practice and 3) interpretation of available scientific and regulatory data and pharmacist’s recommendations for using biosimilars in different cancers.

The Oncology Pharmacotherapy and Applications of Biosimilars (OPAB) Program is supported by Pfizer through an educational grant.

The program launched in October 2021 and consists of 10 online courses (total of 25 hours), supplemented by a Biosimilars Masterclass, which took place at ISOPP’s 2023 Symposium in Spain. You can now access the 10 online modules as part of your ISOPP membership. 



ISOPP acknowledge the Faculty members, Reviewers and Task Force members for their contributions to the OPAB Program.



This program is supported by an educational grant from Pfizer.


If you are an organization or company and wish to discuss collaborating with ISOPP on other projects, please get in contact: president@isopp.org


What people are saying about the course:

Engaging in the ISOPP OPAB program has proven to be a useful experience for the team of pharmacists at the Greenslopes Private Hospital Oncology pharmacy. It has allowed a deeper understanding of biosimilar medicines and their implementation and enhanced the skills required to evaluate biosimilar usage at our site. Additionally, through a comprehensive learning package reviewing numerous cancer states, the OPAB program has given our team more confidence to engage in clinical discussions with prescribers at our site' – Greenslopes Private Hospital, Australia 

The participation in the OPAB program has shown a positive impact in the accessibility of biologics by showing an improvement in accessibility of biologics. This is observed as more patients were able to receive the biologics.  The OPAB program has had an impact on the selection of biologics within the institution through which a policy was put in place. ' – Kenyatta University Teaching, Referral and Research Hospital, Kenya

The OPAB program developed by the ISOPP has increased The University of Ilorin Teaching Hospital (UITH) pharmacists’ knowledge, awareness, and acceptance of biosimilars. Contrary to our perception before the program, biosimilars are available in Nigeria, although most healthcare professionals handle them as generic versions of originator pharmaceutical products. With the knowledge gained from the training program, the oncology pharmacists are better placed to successfully implement biosimilars and foster improved access to this treatment in UITH. ' – The University of Ilorin Teaching Hospital (UITH), Nigeria


Please note that these modules were authored in 2020/2021 and may contain elements of practice that have now been superseded. ISOPP cannot accept responsibility for any errors or omissions or for any consequences from application of information in the course and make no warranty, expressed or implicit with respect to the contents of this course. You must consider professional or specialist advice before taking, or refraining from, any action on the basis of the content of the course or document(s) downloaded